Galunisertib enhances chimeric antigen receptor-modified T cell function

Zhixiong Wang,1,2,3 Qian Liu,1 Na Risu,3 Jiayu Fu,3 Yan Zou,4 Jiaxing Tang,4 Long Li,4 Hui Liu,1 Guomin Zhou,1 Xuekai Zhu,4

1School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, China
2Ma’anshan University, Ma’an Shan, China
3Division of Health Science, Graduate School of Medicine, Osaka University, Osaka, Japan
4Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, Shanghai, China

Correspondence: Xuekai Zhu, Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, 393 Middle Huaxia Road, Pudong, Shanghai 201210, China. Tel. +86.021.20685207. Email: zhuxk@shanghaitech.edu.cn

Key words: CAR T; TGF-β; solid tumor; immunotherapy; immunosuppression.
Supplementary Figure 1.
Galunisertib does not affect the antigen expression on tumor cells. U251 CD133-OE luc or MDA-MB-453 luc was treated with Gal, DMSO or culture medium (D-10) for two days. Cells were stained with antibodies against CD133 or HER2, and then detected by flow cytometry.
**Supplementary Figure 2.**
Galunisertib has no significant effect on the expression of CD69 on CAR T.